-
Q&A
Writing Through ItIn a new book and on her New York Times blog, author Susan Gubar chronicles her experiences living with metastatic cancer.
by Marci A. Landsmann
-
The Power of OneA cancer survivor reflects on the stranger who gave him a second chance at life.
by Robert Henslin
-
Yesterday & Today
Who Loves Ya, Baby?Telly Savalas met his match in bladder cancer. Earlier diagnosis and more aggressive treatment might have made a difference.
by Jocelyn Selim
-
Forward Look
Paying a Steep PriceNew laws are pushing health insurers to make oral cancer drugs affordable.
by Betty Russell
-
Forward Look
Fueling the Pediatric Cancer PipelineNew efforts are needed to push the pace of drug development.
by Leah Lawrence
-
Forward Look
It Takes a VillageImproving pediatric cancer care in developing countries
by Leah Lawrence
-
Forward Look
When the Cancer Doctor Gets CancerQ & A with breast surgeon Susan Love on her new role: cancer survivor.
by Betty Russell
-
Forward Look
The Proof of the Proton Is in the ResultProton beam radiation therapy is expensive and controversial.
by Stephen Ornes
-
Survivor Profile
Macho ManCarlos De La Cuesta is redefining manhood after prostate cancer.
by Jocelyn Selim
-
Q&A
The Legacy of Henrietta LacksAuthor Rebecca Skloot reflects on the contributions of one woman to science and the importance of informed consent in human research.
by Alexandra Goho
A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
Immunotherapy Improves Survival in Bladder CancerNew research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
-
AACR IO: Revolutionizing Treatment through ImmunotherapyThe AACR’s immuno-oncology meeting brings together the leading experts in immunotherapy to accelerate progress in cancer science and medicine.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
